Table 4 ADV and GVHD status before and after ADV-VST infusion for each patient
Patient | Diagnosis | Age | AlloSCT | GVHD status at inclusion | Early GVHD after VSTs (<1 month) | Days of ADV reactivation Since graft | D0 ADV load (×103 copy/mL) | ADV status | Modulation of IS for ADV management | IS at VSTs infusion | Antiviral treatment prior VSTs | Days of VSTs since ADV reactivation | Antiviral treatment after VSTs | ADV load response (decrease > 0.5log) | ADV IR | Early infection (<1 month) | Outcome (ADV clearance) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
01-01 | ALL | 14 | MAC-ATG PHSC MUD | Grade II aGVHD | No | 100 | 1790 | Disease (GT) | None | Cyclo + CST + basiliximab | Cidofovir | 41 | Cidofovir D0-D9 | D14 | Increase at D14 | EBV at D21 | Dead > D180 (D21) |
07-03 | MDS | 2 | RIC-ATG PHSC MUD | Grade I aGVHD | No | 143 | NA | Disease (GT) | None | MMF | Cidofovir | 78 | Cidofovir D11-D24 | UN | Increase at D60 | No | Alive (D21) |
09-04 | ALL | 14 | MAC-ATG PHSC MMUD | Grade II aGVHD + cGVHD | No | 70 | 25.8 | Asymptomatic infection | Stop IS for ADV, restart at D0 | Cyclo + CST | None | 23 | None | D17 | Increase at D14 | EBV at D14 | Alive (D30) |
06-05 | HL | 31 | RIC-ATG PHSC MMUD | Grade II aGVHD + limited cGVHD | Extensive cGVHD (D7) | 215 | 87.1 | Disease (GT) | Stop IS for ADV, restart at D32 | None | None | 49 | None | D45 | Increase at D60 | No | Alive (D180) |
07-06 | AA | 12 | RIC-ATG UCB | Grade II aGVHD | Grade I aGVHD (D14) | 46 | 4.82 | Disease (GT) | None | MMF + CST | Ribavirine | 95 | Ribavirine D0-D40 + Cidofovir D60-D115 | D60 | Increase at D14 | No | Dead > D180 (D90) |
02-08 | ALL | 5 | MAC UCB | Grade III aGVHD | Grade III aGHVD (D14) | 64 | 0.75 | Disease (pulmonary) | Stop IS for VSTs and restart at D12 | None | Cidofovir | 42 | None | D7 | Increase at D14 | Bacteria at D7 | Dead of infection at D132 (D14) |
11-10 | MDS | 27 | MAC-ATG UCB | Grade IV aGVHD | No | 126 | 877 | Disease (GT) | None | Cyclo + CST + Ruxolitinib | Cidofovir | 37 | None | D21 | Increase at D14 | Bacteria at D21 | Alive (D60) |
12-11 | AML | 11Â m | MAC-ATG UCB | No GVHD | No | 18 | 7300 | Disease (GT) | Stop MMF for ADV | Cyclo | Cidofovir | 43 | Ribavirine until D8 | No response | Increase at D14, noresponse at D30 | EBV at D14 | Dead of ADV at D33 |
08-12 | PID | 7Â m | MAC-ATG UCB | No GVHD | No | -14 | 1660 | Disease (GT) | Stop CST for ADV | Cyclo | Cidofovir | 37 | None | D10 | response at D14 | Bacteria at D7 and D21 | Alive (D45) |
01-13 | SS | 8 | MAC-ATG PHSC MMUD | No GVHD | No | 19 | 37.9 | Disease (GT) | Stop IS for ADV | None | Cidofovir | 69 | Cidofovir D6-D23 | D30 | Increase at D30 | No | Alive (D60) |
12-14 | FA | 4 | RIC-ATG UCB | No GVHD | No | 13 | 8.5 | Disease (GT) | None | Cyclo + MMF Stop MMF D4 | Cidofovir | 16 | Brincidofovir D95-D125 + Cidofovir D125-D132 | D70 | Response at D14 | No | Alive (D30) |